FDA Approves Viatris' Ryzumvi Eye Drops for Presbyopia in Adults

According to Viatris' press release, distributed via Placera, the U.S. Food and Drug Administration has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. The announcement is dated October 16, 2026. Presbyopia is the gradual loss of near focusing ability with age. The release says it typically becomes noticeable in the early to mid-40s and calls it a nearly universal condition.

This article is based on the company's press release. We did not review any trial data or an independent FDA notice, and the underlying study paper was not reviewed.

The approval adds an indication to an existing product. According to the release, Ryzumvi is already approved in the U.S. to treat pharmacologically induced mydriasis, meaning pupil dilation caused by certain drugs. The company says it is the only commercially available FDA-approved product for that use. The label for presbyopia covers adults. The mydriasis label covers adults and children aged 3 and older.

The commercial setup matters here. The release says Opus Genetics and Viatris, through an affiliated entity, are parties to a global licensing agreement. It gives Viatris exclusive rights to commercialize the product in the United States. Viatris says it is exploring the potential for a partner in the United States to commercialize Ryzumvi for presbyopia. That wording means no launch plan or partner was announced.

The safety information in the release gives a sense of the trade-offs. In presbyopia, the most common eye-related adverse reactions, reported in more than 5% of subjects, were conjunctival hyperemia (21%) and instillation site irritation (16%). The label advises against use in patients with active ocular inflammation, such as iritis. Contact lens wearers are told to remove lenses before dosing and wait 10 minutes before reinserting them. The release gives no efficacy figures for presbyopia.

What does this mean for the market? That is our interpretation, not a finding from the release. The company is seeking a partner rather than announcing its own launch. That could suggest it sees value in outside commercial capacity for a condition that affects most adults as they age. It could also reflect other priorities. The release does not say. It also gives no pricing, launch timing or comparison with other presbyopia treatments, so competitive positioning cannot be judged from it. This is the weakest part of our argument.

The regulatory path is clearer. Adding an indication to an approved drug lets the company use an existing product in a much larger group of patients. The size of that group follows from the release's description of presbyopia as nearly universal. Whether it becomes a meaningful revenue source depends on factors the release does not address, including demand, pricing and reimbursement. The company's own forward-looking statements list those as uncertainties.

Watch next for whether Viatris names a U.S. commercialization partner, and for the full prescribing information and trial data that would let outsiders judge how well the drops work.

Major Hospitals Open Longevity Clinics, and STAT Asks Whether They Work PPIC Projects California's 65-Plus Labor Force Will Reach 1.8 Million by 2040 FDA Approves Viatris' Ryzumvi Eye Drops for Presbyopia in Adults Wyden Seeks Input on Medicare or Medicaid Universal Home Care Benefit Atrogi's Oral Muscle Drug Linked to 13% Power Gain in Small Study Over 90% of US Nursing Homes Staff Below Acuity-Based Expected Level, LTCCC Says